cetuximab,encorafenib,binimetinib
pfizer,eli lilly,array biopharma
['beacon']
subanalysis of beacon study braf v600e mut in baseline ctdna in 91% of pts (higher tumor volume and levels of ctdna) reactivation of the mapk pathway the most common mechanism of resistance subclonal alterations
#esmo22 
MD, PhD. GI Medical Oncologist @istitutotumori. @myESMO #YOC committee member. European. Beauty seeker. #endowarrior. Tweets are my own.